Skip to main content
Erschienen in: Breast Cancer Research and Treatment 2/2012

01.07.2012 | Epidemiology

Incidence of invasive breast cancer in the presence of competing mortality: the Canadian National Breast Screening Study

verfasst von: Sharareh Taghipour, Dragan Banjevic, Joanne Fernandes, Anthony B. Miller, Neil Montgomery, Bart J. Harvey, Andrew K. S. Jardine

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 2/2012

Einloggen, um Zugang zu erhalten

Abstract

Mortality due to causes other than breast cancer is a potential competing risk which may alter the incidence probability of breast cancer and as such should be taken into account in predictive modelling. We used data from the Canadian National Breast Screening Study (CNBSS), which consist of two randomized controlled trials designed to evaluate the efficacy of mammography among women aged 40–59. The participants in the CNBSS were followed up for incidence of breast cancer and mortality due to breast cancer and other causes; this allowed us to construct a breast cancer risk prediction model while taking into account mortality for the same study population. In this study, we use 1980–1989 as the study period. We exclude the prevalent cancers from the CNBSS to estimate the probability of developing breast cancer, given the fact that women were cancer-free at the beginning of the follow-up. By the end of 1989, from 89,434 women, 944 (1.1 %) were diagnosed with invasive breast cancer, 922 (1.0 %) died from causes other than breast cancer, and 87,568 (97.9 %) were alive and not diagnosed with invasive breast cancer. We constructed a risk prediction model for invasive breast cancer based on 39 risk factors collected at the time of enrolment or the initial physical examination of the breasts. Age at entry (HR 1.07, 95 % CI 1.05–1.10), lumps ever found in left or right breast (HR 1.92, 95 % CI 1.19–3.10), abnormality in the left breast (HR 1.26, 95 % CI 1.07–1.48), history of other breast disease, family history of breast cancer score (HR 1.01, 95 % CI 1.00–1.01), years menstruating (HR 1.02, 95 % CI 1.01–1.03) and nulliparity (HR 1.70, 95 % CI 1.23–2.36) are the model’s predictors. We investigated the effects of time-dependent factors. The model is well calibrated with a moderate discriminatory power (c-index 0.61, 95 % CI 0.59–0.63); we use it to predict the 9-year risk of developing breast cancer for women of different age groups. As an example, we estimated the probability of invasive cancer at 5 years after enrolment to be 0.00448, 0.00556, 0.00691, 0.00863, and 0.01034, respectively, for women aged 40, 45, 50, 55, and 59, all of whom had never noted lumps in their breasts, had 32 years of menstruating, 1–2 live births, no other types of breast disease and no abnormality found in their left breasts. The results of this study can be used by clinicians to identify women at high risk of breast cancer for screening intervention and to recommend a personalized intervention plan. The model can be also utilized by a woman as a breast cancer risk prediction tool.
Literatur
1.
Zurück zum Zitat van Manen JG, Van Dijk PC, Stel VS, Dekker FW, Cleries M, Conte F, Feest T, Kramar R, Leivestad T, Briggs JD, Stengel B, Jager KJ (2007) Confounding effect of comorbidity in survival studies in patients on renal replacement therapy. Nephrol Dial Transplant 22(1):187–195PubMedCrossRef van Manen JG, Van Dijk PC, Stel VS, Dekker FW, Cleries M, Conte F, Feest T, Kramar R, Leivestad T, Briggs JD, Stengel B, Jager KJ (2007) Confounding effect of comorbidity in survival studies in patients on renal replacement therapy. Nephrol Dial Transplant 22(1):187–195PubMedCrossRef
2.
Zurück zum Zitat Dd Rao VK, Iademarco EP, Fraser VJ, Kollef MH (1998) The impact of comorbidity on mortality following in-hospital diagnosis of tuberculosis. Chest 114(5):1244–1252CrossRef Dd Rao VK, Iademarco EP, Fraser VJ, Kollef MH (1998) The impact of comorbidity on mortality following in-hospital diagnosis of tuberculosis. Chest 114(5):1244–1252CrossRef
3.
Zurück zum Zitat Goodkin DA, Bragg-Gresham JL, Koenig KG, Wolfe RA, Akiba T, Andreucci VE, Saito A, Rayner HC, Kurokawa K, Port FK, Held PJ, Young EW (2003) Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan, and the United States: the Dialysis Outcomes and Practice Patterns Study (DOPPS). J Am Soc Nephrol 14(12):3270–3277PubMedCrossRef Goodkin DA, Bragg-Gresham JL, Koenig KG, Wolfe RA, Akiba T, Andreucci VE, Saito A, Rayner HC, Kurokawa K, Port FK, Held PJ, Young EW (2003) Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan, and the United States: the Dialysis Outcomes and Practice Patterns Study (DOPPS). J Am Soc Nephrol 14(12):3270–3277PubMedCrossRef
4.
Zurück zum Zitat Gail MH, Brinton LA, Byar DP, Corle DK, Green SB, Schairer C, Mulvihill JJ (1989) Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 81(24):1879–1886PubMedCrossRef Gail MH, Brinton LA, Byar DP, Corle DK, Green SB, Schairer C, Mulvihill JJ (1989) Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 81(24):1879–1886PubMedCrossRef
5.
Zurück zum Zitat Wolbers M, Koller MT, Witteman JCM, Steyerberg EW (2009) Prognostic models with competing risks methods and application to coronary risk prediction. Epidemiology 20(4):555–561PubMedCrossRef Wolbers M, Koller MT, Witteman JCM, Steyerberg EW (2009) Prognostic models with competing risks methods and application to coronary risk prediction. Epidemiology 20(4):555–561PubMedCrossRef
6.
Zurück zum Zitat Mell LK, Jeong JH, Nichols MA, Polite BN, Weichselbaum RR, Chmura SJ (2010) Predictors of competing mortality in early breast cancer. Cancer 116(23):5365–5373PubMedCrossRef Mell LK, Jeong JH, Nichols MA, Polite BN, Weichselbaum RR, Chmura SJ (2010) Predictors of competing mortality in early breast cancer. Cancer 116(23):5365–5373PubMedCrossRef
7.
Zurück zum Zitat Lughezzani G, Sun M, Shariat S, Budäus L, Thuret R, Jeldres C, Liberman D, Montorsi F, Perrotte P, Karakiewicz PI (2011) A population-based competing-risks analysis of the survival of patients treated with radical cystectomy for bladder cancer. Cancer 117(1):103–109PubMedCrossRef Lughezzani G, Sun M, Shariat S, Budäus L, Thuret R, Jeldres C, Liberman D, Montorsi F, Perrotte P, Karakiewicz PI (2011) A population-based competing-risks analysis of the survival of patients treated with radical cystectomy for bladder cancer. Cancer 117(1):103–109PubMedCrossRef
8.
Zurück zum Zitat Daskivich TJ, Chamie K, Kwan L, Labo J, Dash A, Greenfield S, Litwin MS (2011) Comorbidity and competing risks for mortality in men with prostate cancer. Cancer 117(20):4642–4650CrossRef Daskivich TJ, Chamie K, Kwan L, Labo J, Dash A, Greenfield S, Litwin MS (2011) Comorbidity and competing risks for mortality in men with prostate cancer. Cancer 117(20):4642–4650CrossRef
9.
Zurück zum Zitat Fine JP, Gray RJ (1999) A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94(446):496–509CrossRef Fine JP, Gray RJ (1999) A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94(446):496–509CrossRef
10.
Zurück zum Zitat Satagopan JM, Ben-Porat L, Berwick M, Robson M, Kutler D, Auerbach AD (2004) Minireview: a note on competing risks in survival data analysis. Br J Cancer 91(7):1229–1235PubMedCrossRef Satagopan JM, Ben-Porat L, Berwick M, Robson M, Kutler D, Auerbach AD (2004) Minireview: a note on competing risks in survival data analysis. Br J Cancer 91(7):1229–1235PubMedCrossRef
11.
Zurück zum Zitat Glynn RJ, Rosner B (2005) Comparison of risk factors for the competing risks of coronary heart disease, stroke, and venous thromboembolism. Am J Epidemiol 162(10):975–982PubMedCrossRef Glynn RJ, Rosner B (2005) Comparison of risk factors for the competing risks of coronary heart disease, stroke, and venous thromboembolism. Am J Epidemiol 162(10):975–982PubMedCrossRef
12.
Zurück zum Zitat Melberg T, Nygard OK, Kuiper KK, Nordrehaug JE (2010) Competing risk analysis of events 10 years after revascularization. Scand Cardiovasc J 44(5):279–288PubMedCrossRef Melberg T, Nygard OK, Kuiper KK, Nordrehaug JE (2010) Competing risk analysis of events 10 years after revascularization. Scand Cardiovasc J 44(5):279–288PubMedCrossRef
13.
Zurück zum Zitat Forsblom C, Harjutsalo V, Thorn LM, Wadén J, Tolonen N, Saraheimo M, Gordin D, Moran JL, Thomas MC, Groop PH (2011) Competing-risk analysis of ESRD and death among patients with type 1 diabetes and macroalbuminuria. J Am Soc Nephrol 22(3):537–544PubMedCrossRef Forsblom C, Harjutsalo V, Thorn LM, Wadén J, Tolonen N, Saraheimo M, Gordin D, Moran JL, Thomas MC, Groop PH (2011) Competing-risk analysis of ESRD and death among patients with type 1 diabetes and macroalbuminuria. J Am Soc Nephrol 22(3):537–544PubMedCrossRef
14.
Zurück zum Zitat Miller AB, Baines CJ, To T, Wall C (1992) Canadian national breast screening study—1. Breast cancer detection and death rates among women age 40–49 years. Can Med Assoc J 147(10):1459–1476 Miller AB, Baines CJ, To T, Wall C (1992) Canadian national breast screening study—1. Breast cancer detection and death rates among women age 40–49 years. Can Med Assoc J 147(10):1459–1476
15.
Zurück zum Zitat Miller AB, Baines CJ, To T, Wall C (1992) Canadian national breast screening study—2. Breast cancer detection and death rates among women age 50–59 years. Can Med Assoc J 147(10):1477–1488 Miller AB, Baines CJ, To T, Wall C (1992) Canadian national breast screening study—2. Breast cancer detection and death rates among women age 50–59 years. Can Med Assoc J 147(10):1477–1488
16.
Zurück zum Zitat Miller AB, To T, Baines CJ, Wall C (2002) The Canadian National Breast Screening Study-1: breast cancer mortality after 11 to 16 years of follow-up: a randomized screening trial of mammography in women age 40 to 49 years. Ann Intern Med 137(5 Part 1):305–312PubMed Miller AB, To T, Baines CJ, Wall C (2002) The Canadian National Breast Screening Study-1: breast cancer mortality after 11 to 16 years of follow-up: a randomized screening trial of mammography in women age 40 to 49 years. Ann Intern Med 137(5 Part 1):305–312PubMed
17.
Zurück zum Zitat Miller AB, To T, Baines CJ, Wall C (2002) Canadian National Breast Screening Study-2: 13-year results of a randomized trial in women aged 50–59 years. J Natl Cancer 192(18):1490–1499 Miller AB, To T, Baines CJ, Wall C (2002) Canadian National Breast Screening Study-2: 13-year results of a randomized trial in women aged 50–59 years. J Natl Cancer 192(18):1490–1499
18.
Zurück zum Zitat Cui Y, Miller AB, Rohan TE (2006) Cigarette smoking and breast cancer risk: update of a prospective cohort study. Breast Cancer Res Treat 100(3):293–299PubMedCrossRef Cui Y, Miller AB, Rohan TE (2006) Cigarette smoking and breast cancer risk: update of a prospective cohort study. Breast Cancer Res Treat 100(3):293–299PubMedCrossRef
19.
Zurück zum Zitat Harvey BJ, Miller AB, Baines CJ, Corey PN (1997) Effect of breast self-examination techniques on the risk of death from breast cancer. Can Med Assoc J 157(9):1205–1212 Harvey BJ, Miller AB, Baines CJ, Corey PN (1997) Effect of breast self-examination techniques on the risk of death from breast cancer. Can Med Assoc J 157(9):1205–1212
20.
Zurück zum Zitat Jain MG, Ferrence RG, Rehm JT, Bondy SJ, Rohan TE, Ashley MJ, Cohen JE, Miller AB (2000) Alcohol and breast cancer mortality in a cohort study. Breast Cancer Res Treat 64(2):201–209PubMedCrossRef Jain MG, Ferrence RG, Rehm JT, Bondy SJ, Rohan TE, Ashley MJ, Cohen JE, Miller AB (2000) Alcohol and breast cancer mortality in a cohort study. Breast Cancer Res Treat 64(2):201–209PubMedCrossRef
21.
Zurück zum Zitat Schechter MT, Miller AB, Howe GR (1985) Cigarette smoking and breast cancer: a case control-study of screening program participants. Am J Epidemiol 121(4):479–487PubMed Schechter MT, Miller AB, Howe GR (1985) Cigarette smoking and breast cancer: a case control-study of screening program participants. Am J Epidemiol 121(4):479–487PubMed
22.
Zurück zum Zitat Rohan TE, Howe GR, Friedenreich CM, Jain M, Miller AB (1993) Dietary fiber, vitamin A, C, and E, and risk of breast cancer: a cohort study. Cancer Cause Control 4(1):29–37CrossRef Rohan TE, Howe GR, Friedenreich CM, Jain M, Miller AB (1993) Dietary fiber, vitamin A, C, and E, and risk of breast cancer: a cohort study. Cancer Cause Control 4(1):29–37CrossRef
23.
Zurück zum Zitat Kabat GC, Miller AB, Jain M, Rohan TE (2007) Dietary iron and heme iron intake and risk of breast cancer: a prospective cohort study. Cancer Epidemiol Biomark Prev 16(6):1306–1308CrossRef Kabat GC, Miller AB, Jain M, Rohan TE (2007) Dietary iron and heme iron intake and risk of breast cancer: a prospective cohort study. Cancer Epidemiol Biomark Prev 16(6):1306–1308CrossRef
24.
Zurück zum Zitat Schechter MT, Miller AB, Howe GR, Baines CJ, Craib KJ, Wall C (1989) Cigarette smoking and breast cancer: case control studies of prevalent and incident cancer in the Canadian National Breast Screening Study. Am J Epidemiol 130(2):213–220PubMed Schechter MT, Miller AB, Howe GR, Baines CJ, Craib KJ, Wall C (1989) Cigarette smoking and breast cancer: case control studies of prevalent and incident cancer in the Canadian National Breast Screening Study. Am J Epidemiol 130(2):213–220PubMed
25.
Zurück zum Zitat Rohan TE, Jain MG, Howe GR, Miller AB (2000) Dietary folate consumption and breast cancer risk. J Natl Cancer 92(3):266–269CrossRef Rohan TE, Jain MG, Howe GR, Miller AB (2000) Dietary folate consumption and breast cancer risk. J Natl Cancer 92(3):266–269CrossRef
26.
Zurück zum Zitat Silvera SA, Jain M, Howe GR, Miller AB, Rohan TE (2006) Energy balance and breast cancer risk: a prospective cohort study. Breast Cancer Res Treat 97(1):97–106PubMedCrossRef Silvera SA, Jain M, Howe GR, Miller AB, Rohan TE (2006) Energy balance and breast cancer risk: a prospective cohort study. Breast Cancer Res Treat 97(1):97–106PubMedCrossRef
27.
Zurück zum Zitat Rohan TE, Miller AB (1999) A cohort study of oral contraceptives and risk of benign breast disease. Int J Cancer 82(2):191–196PubMedCrossRef Rohan TE, Miller AB (1999) A cohort study of oral contraceptives and risk of benign breast disease. Int J Cancer 82(2):191–196PubMedCrossRef
28.
Zurück zum Zitat Holowaty PH, Miller AB, Baines CJ, Risch H (1993) Canadian National Breast Screening Study: first screen results as predictors of future breast cancer risk. Cancer Epidemiol Biomark Prev 2:11–19 Holowaty PH, Miller AB, Baines CJ, Risch H (1993) Canadian National Breast Screening Study: first screen results as predictors of future breast cancer risk. Cancer Epidemiol Biomark Prev 2:11–19
31.
Zurück zum Zitat US Preventive Services Task Force (2005) Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: recommendation statement. Ann Intern Med 143:355–361 US Preventive Services Task Force (2005) Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: recommendation statement. Ann Intern Med 143:355–361
33.
Zurück zum Zitat Kalbfleisch JD, Prentice RL (1980) The statistical analysis of failure time data, 1st edn. Wiley, New York Kalbfleisch JD, Prentice RL (1980) The statistical analysis of failure time data, 1st edn. Wiley, New York
34.
Zurück zum Zitat Chen J, Pee D, Ayyagari R, Graubard B, Schairer C, Byrne C, Benichou J, Gail MH (2006) Projecting absolute invasive breast cancer risk in white women with a model that includes mammographic density. J Natl Cancer Inst 98(17):1215–1226PubMedCrossRef Chen J, Pee D, Ayyagari R, Graubard B, Schairer C, Byrne C, Benichou J, Gail MH (2006) Projecting absolute invasive breast cancer risk in white women with a model that includes mammographic density. J Natl Cancer Inst 98(17):1215–1226PubMedCrossRef
35.
Zurück zum Zitat Gail MH (2008) Discriminatory accuracy from single-nucleotide polymorphisms in models to predict breast cancer risk. J Natl Cancer Inst 100(14):1037–1041PubMedCrossRef Gail MH (2008) Discriminatory accuracy from single-nucleotide polymorphisms in models to predict breast cancer risk. J Natl Cancer Inst 100(14):1037–1041PubMedCrossRef
37.
Zurück zum Zitat Ahmed HG, Ali AS, Almobarak AO (2010) Frequency of breast cancer among Sudanese patients with breast palpable lumps. Indian J Cancer 47(1):48–51CrossRef Ahmed HG, Ali AS, Almobarak AO (2010) Frequency of breast cancer among Sudanese patients with breast palpable lumps. Indian J Cancer 47(1):48–51CrossRef
38.
Zurück zum Zitat Weiss HA, Devesa SS, Brinton LA (1996) Laterality of breast cancer in the United States. Cancer Causes Control 7(5):539–543PubMedCrossRef Weiss HA, Devesa SS, Brinton LA (1996) Laterality of breast cancer in the United States. Cancer Causes Control 7(5):539–543PubMedCrossRef
Metadaten
Titel
Incidence of invasive breast cancer in the presence of competing mortality: the Canadian National Breast Screening Study
verfasst von
Sharareh Taghipour
Dragan Banjevic
Joanne Fernandes
Anthony B. Miller
Neil Montgomery
Bart J. Harvey
Andrew K. S. Jardine
Publikationsdatum
01.07.2012
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 2/2012
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-012-2113-6

Weitere Artikel der Ausgabe 2/2012

Breast Cancer Research and Treatment 2/2012 Zur Ausgabe

Blutdrucksenkung könnte Uterusmyome verhindern

Frauen mit unbehandelter oder neu auftretender Hypertonie haben ein deutlich erhöhtes Risiko für Uterusmyome. Eine Therapie mit Antihypertensiva geht hingegen mit einer verringerten Inzidenz der gutartigen Tumoren einher.

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

16.05.2024 Zielgerichtete Therapie Nachrichten

Trastuzumab deruxtecan scheint auch jenseits von Lungenkrebs gut gegen solide Tumoren mit HER2-Mutationen zu wirken. Dafür sprechen die Daten einer offenen Pan-Tumor-Studie.

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

15.05.2024 Mammakarzinom Nachrichten

Frauen mit lokalem oder metastasiertem Brustkrebs, die Statine einnehmen, haben eine niedrigere krebsspezifische Mortalität als Patientinnen, die dies nicht tun, legen neue Daten aus den USA nahe.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.